| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Asberg, B Mårtensso. Serotonin selective antidepressant drugs: past, present, future. Clinical neuropharmacology. vol 16 Suppl 3. 1994-04-21. PMID:8131153. |
drugs that selectively affect 5-ht neurons have proved to be uptake inhibitors--including fluoxetine, fluvoxamine, paroxetine, sertraline, and citalopram--and are now available. |
1994-04-21 |
2023-08-12 |
Not clear |
| M Langemark, J Olese. Sulpiride and paroxetine in the treatment of chronic tension-type headache. An explanatory double-blind trial. Headache. vol 34. issue 1. 1994-04-15. PMID:8132436. |
a serotonin re-uptake inhibitor, paroxetine (20-30 mg daily), and a dopamine antagonist, sulpiride (200-400 mg daily) were compared in a randomized, double-blind, response-conditional cross-over pilot study in 50 non-depressed patients with chronic tension-type headache. |
1994-04-15 |
2023-08-12 |
Not clear |
| K Brøse. The pharmacogenetics of the selective serotonin reuptake inhibitors. The Clinical investigator. vol 71. issue 12. 1994-04-14. PMID:8124052. |
citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline are selective serotonin reuptake inhibitors (ssris), which are thought to act as antidepressants through their ability to inhibit presynaptic serotonin reuptake in the brain. |
1994-04-14 |
2023-08-12 |
Not clear |
| M J Owens, C B Nemerof. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clinical chemistry. vol 40. issue 2. 1994-03-24. PMID:7508830. |
these findings include the following: (a) reduced cerebrospinal fluid (csf) concentrations of 5-hydroxyindoleacetic acid (5-hiaa), the major metabolite of serotonin (5-ht) in drug-free depressed patients; (b) reduced concentrations of 5-ht and 5-hiaa in postmortem brain tissue of depressed and (or) suicidal patients; (c) decreased plasma tryptophan concentrations in depressed patients and a profound relapse in remitted depressed patients who have responded to a serotonergic antidepressant when brain tryptophan availability is reduced; (d) in general, all clinically efficacious antidepressants augment 5-ht neurotransmission following chronic treatment; (e) clinically efficacious antidepressant action by all inhibitors of 5-ht uptake; (f) increases in the density of 5-ht2 binding sites in postmortem brain tissue of depressed patients and suicide victims, as well as in platelets of drug-free depressed patients; (g) decreased number of 5-ht transporter (determined with [3h]imipramine or [3h]paroxetine) binding sites in postmortem brain tissue of suicide victims and depressed patients and in platelets of drug-free depressed patients. |
1994-03-24 |
2023-08-12 |
Not clear |
| C B Nemerof. Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression. Journal of clinical psychopharmacology. vol 13. issue 6 Suppl 2. 1994-03-23. PMID:8106649. |
paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression. |
1994-03-23 |
2023-08-12 |
Not clear |
| C B Nemerof. Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression. Journal of clinical psychopharmacology. vol 13. issue 6 Suppl 2. 1994-03-23. PMID:8106649. |
paroxetine is a novel phenylpiperidine compound that is a potent and selective serotonin reuptake inhibitor. |
1994-03-23 |
2023-08-12 |
Not clear |
| C B Nemerof. Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression. Journal of clinical psychopharmacology. vol 13. issue 6 Suppl 2. 1994-03-23. PMID:8106649. |
as with other selective serotonin reuptake inhibitors, the most common side effect associated with paroxetine treatment is nausea, although this effect rarely leads to dose reduction or drug discontinuation. |
1994-03-23 |
2023-08-12 |
Not clear |
| J Tigno. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. Journal of clinical psychopharmacology. vol 13. issue 6 Suppl 2. 1994-03-23. PMID:8106650. |
paroxetine is a novel phenylpiperidine antidepressant agent that acts as a potent and selective inhibitor of serotonin reuptake. |
1994-03-23 |
2023-08-12 |
human |
| L Lima, C Schmee. Characterization of serotonin transporter in goldfish retina by the binding of [3H]paroxetine and the uptake of [3H]serotonin: modulation by light. Journal of neurochemistry. vol 62. issue 2. 1994-03-02. PMID:8294915. |
characterization of serotonin transporter in goldfish retina by the binding of [3h]paroxetine and the uptake of [3h]serotonin: modulation by light. |
1994-03-02 |
2023-08-12 |
Not clear |
| L Lima, C Schmee. Characterization of serotonin transporter in goldfish retina by the binding of [3H]paroxetine and the uptake of [3H]serotonin: modulation by light. Journal of neurochemistry. vol 62. issue 2. 1994-03-02. PMID:8294915. |
the serotonin (5-ht) uptake system of goldfish retina was evaluated by the binding of [3h]paroxetine to membrane preparations and the uptake of [3h]5-ht into isolated cells from goldfish retina. |
1994-03-02 |
2023-08-12 |
Not clear |
| L Lima, C Schmee. Characterization of serotonin transporter in goldfish retina by the binding of [3H]paroxetine and the uptake of [3H]serotonin: modulation by light. Journal of neurochemistry. vol 62. issue 2. 1994-03-02. PMID:8294915. |
the order of potency of inhibitors of [3h]paroxetine binding was imipramine > 5-methoxy-n,n- dimethyltryptamine > desipramine > fluoxetine > citalopram > 5-ht. |
1994-03-02 |
2023-08-12 |
Not clear |
| J K Staley, M Basile, D D Flynn, D C Mas. Visualizing dopamine and serotonin transporters in the human brain with the potent cocaine analogue [125I]RTI-55: in vitro binding and autoradiographic characterization. Journal of neurochemistry. vol 62. issue 2. 1994-03-02. PMID:8294917. |
the rank order of potency for inhibition of [125i]rti-55 binding to cerebral cortex membranes (paroxetine > citalopram > gbr 12909 > or = mazindol > or = nisoxetine > benztropine) suggests that [125i]rti-55 labels the serotonin transporter in the human occipital cortex. |
1994-03-02 |
2023-08-12 |
human |
| Y Pélicier, P Schaeffe. [Multicenter double-blind study comparing the efficacy and tolerance of paroxetine and clomipramine in reactive depression in the elderly patient]. L'Encephale. vol 19. issue 3. 1994-02-07. PMID:8275912. |
in the paroxetine group, many of the events were typical of the gastrointestinal side-effects associated with 5-ht uptake inhibitor therapy. |
1994-02-07 |
2023-08-12 |
Not clear |
| A M Andrews, D L Murph. 2'-NH2-MPTP in Swiss Webster mice: evidence for long-term (6-month) depletions in cortical and hippocampal serotonin and norepinephrine, differential protection by selective uptake inhibitors or clorgyline and functional changes in central serotonin neurotransmission. The Journal of pharmacology and experimental therapeutics. vol 267. issue 3. 1994-01-27. PMID:8263805. |
pretreatment with the 5-ht-selective uptake inhibitors, fluoxetine or paroxetine, or with the ne-selective uptake inhibitor, desipramine, prevented decreases in cortical and hippocampal 5-ht and ne, respectively, 3 weeks after 2'-nh2-mptp (4 x 20 mg/kg). |
1994-01-27 |
2023-08-12 |
mouse |
| P Cumming, A Gjedd. Kinetics of the uptake of [3H]paroxetine in the rat brain. Synapse (New York, N.Y.). vol 15. issue 2. 1994-01-19. PMID:8259523. |
paroxetine, an antidepressant with a high affinity for serotonin (5-ht) re-uptake sites, is a potential tracer of these sites. |
1994-01-19 |
2023-08-12 |
rat |
| F Molina-Holgado, E Molina-Holgado, M L Leret, M I González, T A Reade. Distribution of indoleamines and [3H]paroxetine binding in rat brain regions following acute or perinatal delta 9-tetrahydrocannabinol treatments. Neurochemical research. vol 18. issue 11. 1994-01-13. PMID:7504790. |
the effects of delta 9-tetrahydrocannabinol (delta 9-thc) administration on the central serotoninergic system were evaluated by biochemical assays of tissue levels of indoleamines; a measure of the serotonin (5-ht) innervation was obtained by using [3h]paroxetine as a marker of 5-ht uptake sites. |
1994-01-13 |
2023-08-12 |
rat |
| F Molina-Holgado, E Molina-Holgado, M L Leret, M I González, T A Reade. Distribution of indoleamines and [3H]paroxetine binding in rat brain regions following acute or perinatal delta 9-tetrahydrocannabinol treatments. Neurochemical research. vol 18. issue 11. 1994-01-13. PMID:7504790. |
there were no changes in 5-ht uptake site density, determined by [3h]paroxetine binding, except for an increase (+50%) in the cingulate cortex of perinatal-treated rats when compared to acutely-treated animals. |
1994-01-13 |
2023-08-12 |
rat |
| N E Rowland, A N Kalehua, B H Li, S L Semple-Rowland, W J Strei. Loss of serotonin uptake sites and immunoreactivity in rat cortex after dexfenfluramine occur without parallel glial cell reactions. Brain research. vol 624. issue 1-2. 1994-01-13. PMID:8252414. |
the frontal cortices of rats which received either d,l- or d-fenfluramine (dfen) for 4 days were examined 18 h to 2 weeks following treatment for changes in synaptosomal uptake of serotonin (5ht), paroxetine binding, 5ht-immunoreactivity (5ht-ir), and both astrocytic (gfap) and microglial markers. |
1994-01-13 |
2023-08-12 |
rat |
| N E Rowland, A N Kalehua, B H Li, S L Semple-Rowland, W J Strei. Loss of serotonin uptake sites and immunoreactivity in rat cortex after dexfenfluramine occur without parallel glial cell reactions. Brain research. vol 624. issue 1-2. 1994-01-13. PMID:8252414. |
consistent with previous reports, d,l- and dfen produced dose-dependent losses of both 5ht uptake and paroxetine binding, and loss of 5ht-ir which coincided with an abnormal or 'swollen' appearance of immunoreactive axon processes. |
1994-01-13 |
2023-08-12 |
rat |
| T L Sherman, C J McDougle, L H Pric. Paroxetine: a new serotonin reuptake inhibitor for the treatment of depression. Connecticut medicine. vol 57. issue 9. 1994-01-13. PMID:8252846. |
paroxetine: a new serotonin reuptake inhibitor for the treatment of depression. |
1994-01-13 |
2023-08-12 |
Not clear |